1College of Pharmaceutical Sciences Pelita Mas Palu, Central Sulawesi94111, Indonesia
2Department of Pharmacy, Faculty of Pharmaceutical, Tadulako University, Central Sulawesi94111, Indonesia
*Corresponding Author E-mail: viani.anggi@gmail.com
Online published on 13 June, 2022.
Breast Cancer is one of the diseases, which the ranks are first on death to the female sex. breast cancer characterized by the growth of uncontrolled breast cancer cells and ability to attack the local organs like as metastases and spread in breast tisue including ducts and lobules. Alternative treatment for breast cancer is combined with chemotherapy and chemopreventive non-toxic agent to breast cancer cells.
The research of the study is to evaluate potential synergism the in-vitro cytotoxicity combination effects from a combination of the Abelmoschus manihot (L.) Medik of (N-Hexane) extracts and Doxorubicin in breast cancer 4T1 cells line.
The study is suggested combination effects of Abelmoschus manihot (L.) Medik of (N-Hexane) extracts and Doxorubicin in breast cancer 4T1 cells line, where carried out against with use table of concentration from Abelmoschus manihot (L.) Medik extracts (N-Hexane) and Doxorubicin as a Chemotherapy agent.
The potential of Abelmoschus manihot (L.) Medik of n-hexane extract can be combination with cytotoxicity agent Doxorubicin on 4T1 breast cancer cells line with concentration of N-Hexane extract 185,0 µg/ml and the concentration of Doxorubicin 25 nM, where the Combination Index (CI) values 0,89 < 1 shows synergist combination.
The Abelmoschus manihot (L.) Medik of n-hexane extract is synergism with cytotoxic agent Doxorubicin in 4T1 breast cancer cells line.
Combination effects, Abelmoschus manihot (L.) Medik of n-hexane extract, Doxorubicin, 4T1 cells line
